Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Sci Rep ; 10(1): 887, 2020 01 21.
Artigo em Inglês | MEDLINE | ID: mdl-31965023

RESUMO

Crigler Najjar Syndrome type I (CNSI) is a rare recessive disorder caused by mutations in the Ugt1a1 gene. There is no permanent cure except for liver transplantation, and current therapies present several shortcomings. Since stem cell-based therapy offers a promising alternative for the treatment of this disorder, we evaluated the therapeutic potential of human liver stem cells (HLSC) in immune-compromised NOD SCID Gamma (NSG)/Ugt1-/- mice, which closely mimic the pathological manifestations in CNSI patients. To assess whether HLSC expressed UGT1A1, decellularised mouse liver scaffolds were repopulated with these cells. After 15 days' culture ex vivo, HLSC differentiated into hepatocyte-like cells showing UGT1A1 expression and activity. For the in vivo human cell engraftment and recovery experiments, DiI-labelled HLSC were injected into the liver of 5 days old NSG/Ugt1-/- pups which were analysed at postnatal Day 21. HLSC expressed UGT1A1 in vivo, induced a strong decrease in serum unconjugated bilirubin, thus significantly improving phenotype and survival compared to untreated controls. A striking recovery from brain damage was also observed in HLSC-injected mutant mice versus controls. Our proof-of-concept study shows that HLSC express UGT1A1 in vivo and improve the phenotype and survival of NSG/Ugt1-/- mice, and show promises for the treatment of CNSI.


Assuntos
Síndrome de Crigler-Najjar/terapia , Glucuronosiltransferase/metabolismo , Fígado/citologia , Células-Tronco/metabolismo , Animais , Bilirrubina/sangue , Encéfalo/patologia , Diferenciação Celular , Síndrome de Crigler-Najjar/imunologia , Síndrome de Crigler-Najjar/mortalidade , Síndrome de Crigler-Najjar/patologia , Modelos Animais de Doenças , Glucuronosiltransferase/genética , Hepatócitos/citologia , Humanos , Fígado/patologia , Camundongos SCID , Fenótipo , Transplante de Células-Tronco , Células-Tronco/imunologia
2.
Hum Gene Ther ; 30(10): 1297-1305, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31502485

RESUMO

Adeno-associated virus (AAV) vector-mediated gene therapy is currently evaluated as a potential treatment for Crigler-Najjar syndrome (CN) (NCT03466463). Pre-existing immunity to AAV is known to hinder gene transfer efficacy, restricting enrollment of seropositive subjects in ongoing clinical trials. We assessed the prevalence of anti-AAV serotype 8 (AAV8) neutralizing antibodies (NAbs) in subjects affected by CN and investigated the impact of low NAb titers (<1:5) on liver gene transfer efficacy in an in vivo passive immunization model. A total of 49 subjects with a confirmed molecular diagnosis of CN were included in an international multicenter study (NCT02302690). Pre-existing NAbs against AAV8 were detected in 30.6% (15/49) of screened patients and, in the majority of positive cases, cross-reactivity to AAV2 and AAV5 was detected. To investigate the impact of low NAbs on AAV vector-mediated liver transduction efficiency, adult wild-type C57BL/6 mice were passively immunized with pooled human donor-derived immunoglobulins to achieve titers of up to 1:3.16. After immunization, animals were injected with different AAV8 vector preparations. Hepatic vector gene copy number was unaffected by low anti-AAV8 NAb titers when column-purified AAV vector batches containing both full and empty capsids were used. In summary, although pre-existing anti-AAV8 immunity can be found in about a third of subjects affected by CN, low anti-AAV8 NAb titers are less likely to affect liver transduction efficiency when using AAV vector preparations manufactured to contain both full and empty capsids. These findings have implications for the design of liver gene transfer clinical trials and for the definition of inclusion criteria related to seropositivity of potential participants.


Assuntos
Anticorpos Neutralizantes/biossíntese , Anticorpos Antivirais/biossíntese , Síndrome de Crigler-Najjar/terapia , Dependovirus/genética , Terapia Genética/métodos , Glucuronosiltransferase/genética , Adolescente , Adulto , Animais , Bilirrubina/imunologia , Bilirrubina/metabolismo , Capsídeo/imunologia , Capsídeo/metabolismo , Criança , Pré-Escolar , Síndrome de Crigler-Najjar/genética , Síndrome de Crigler-Najjar/imunologia , Síndrome de Crigler-Najjar/patologia , Dependovirus/imunologia , Antagonistas de Aminoácidos Excitatórios/uso terapêutico , Feminino , Expressão Gênica , Glucuronosiltransferase/deficiência , Glucuronosiltransferase/imunologia , Células HEK293 , Humanos , Imunidade Inata , Imunização Passiva , Fígado/imunologia , Fígado/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Fenobarbital/uso terapêutico , Fototerapia/métodos , Plasmídeos/química , Plasmídeos/metabolismo , Transfecção
3.
Am J Transplant ; 16(3): 1021-30, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-26523372

RESUMO

Clinical hepatocyte transplantation is hampered by low engraftment rates and gradual loss of function resulting in incomplete correction of the underlying disease. Preconditioning with partial hepatectomy improves engraftment in animal studies. Our aim was to study safety and efficacy of partial hepatectomy preconditioning in clinical hepatocyte transplantation. Two patients with Crigler-Najjar syndrome type I underwent liver resection followed by hepatocyte transplantation. A transient increase of hepatocyte growth factor was seen, suggesting that this procedure provides a regenerative stimulus. Serum bilirubin was decreased by 50%, and presence of bilirubin glucuronides in bile confirmed graft function in both cases; however, graft function was lost due to discontinuation of immunosuppressive therapy in one patient. In the other patient, serum bilirubin gradually increased to pretransplant concentrations after ≈600 days. In both cases, loss of graft function was temporally associated with emergence of human leukocyte antigen donor-specific antibodies (DSAs). In conclusion, partial hepatectomy in combination with hepatocyte transplantation was safe and induced a robust release of hepatocyte growth factor, but its efficacy on hepatocyte engraftment needs to be evaluated with additional studies. To our knowledge, this study provides the first description of de novo DSAs after hepatocyte transplantation associated with graft loss.


Assuntos
Formação de Anticorpos/imunologia , Síndrome de Crigler-Najjar/imunologia , Rejeição de Enxerto/etiologia , Antígenos HLA/imunologia , Hepatectomia/efeitos adversos , Hepatócitos/transplante , Transplante de Fígado/efeitos adversos , Doadores de Tecidos , Adolescente , Adulto , Criança , Síndrome de Crigler-Najjar/cirurgia , Feminino , Humanos , Lactente , Masculino , Complicações Pós-Operatórias , Prognóstico
4.
Hum Gene Ther ; 22(5): 605-12, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21222531

RESUMO

Adeno-associated virus (AAV) liver-directed gene therapy seems a feasible treatment for Crigler-Najjar syndrome type I, an inherited liver disorder characterized by severe unconjugated hyperbilirubinemia. Transient immunosuppression coupled with vector administration seems needed to overcome host immune responses that prevent long-term expression in patients. The immunosuppressive mycophenolate mofetil (MMF), which inhibits de novo synthesis of purines, is a promising candidate. To investigate the potential use of MMF in patients with Crigler-Najjar syndrome, we studied its effect on single-stranded AAV (ssAAV)-mediated correction of hyperbilirubinemia in the relevant preclinical model, the Gunn rat. Although MMF was well tolerated and effective it also impaired the efficacy of ssAAV. Subsequent in vitro studies showed that this effect is not specific for UGT1A deficiency. In fact, clinical relevant concentrations of mycophenolic acid (MPA), the active compound of MMF, also impair the transduction of HEK-293T cells by ssAAV. Because this effect was reversed by guanosine addition, it seems that intracellular levels of this nucleotide become limited, suggesting that MPA impairs second-strand DNA synthesis. This is corroborated by observations that MPA did not impair transduction of 293T cells by a self-complementary AAV (scAAV) vector and that MMF did not reduce the scAAV efficacy in the Gunn rat. In conclusion, MMF impairs ssAAV-mediated liver-directed gene therapy, which is relevant for the use of this immunosuppressive agent with single-stranded vectors. Furthermore, because this effect is due to impaired second-strand synthesis, the use of MMF with scAAV seems warranted.


Assuntos
Dependovirus/efeitos dos fármacos , Terapia Genética/métodos , Vetores Genéticos/genética , Imunossupressores/farmacologia , Ácido Micofenólico/análogos & derivados , Transdução Genética/métodos , Animais , Bilirrubina/sangue , Linhagem Celular , Síndrome de Crigler-Najjar/genética , Síndrome de Crigler-Najjar/imunologia , Síndrome de Crigler-Najjar/terapia , Primers do DNA/genética , Replicação do DNA/efeitos dos fármacos , Ensaio de Imunoadsorção Enzimática , Vetores Genéticos/efeitos dos fármacos , Humanos , Modelos Lineares , Ácido Micofenólico/farmacologia , Reação em Cadeia da Polimerase , Ratos , Ratos Gunn
6.
Gastroenterology ; 139(3): 999-1007, 1007.e1-2, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20546738

RESUMO

BACKGROUND & AIMS: Crigler-Najjar type 1 (CN-I) is an inherited liver disease caused by an absence of bilirubin-uridine 5'-diphosphate-glucuronosyltransferase (UGT1A1) activity. It results in life-threatening levels of unconjugated bilirubin, and therapeutic options are limited. We used adult Gunn rats (an animal model of the disease) to evaluate the efficiency of lentiviral-based gene therapy to express UGT1A1 in liver. METHODS: Gunn rats were given intraportal injections of VSVG-pseudotyped lentiviral vectors that encode UGT1A1 under the control of a liver-specific transthyretin promoter (mTTR.hUGT1A1); this vector does not contain target sequences for miR-142, a microRNA that is expressed specifically in hematopoietic cells. Rats were also injected with the vector mTTR.hUGT1A1.142T, which contains 4 copies of the miR-142 target sequences; its messenger RNA should be degraded in antigen-presenting cells. Bilirubinemia was monitored, and the presence of transduced hepatocytes was analyzed by quantitative polymerase chain reaction. Vector expression was tested in vitro in rat hematopoietic cells. RESULTS: In Gunn rats, bilirubin levels normalized 2 weeks after administration of mTTR.hUGT1A1. However, hyperbilirubinemia resumed 8 weeks after vector administration, concomitant with the induction of an immune response. In contrast, in rats injected with mTTR-UGT1A1.142T, bilirubin levels normalized for up to 6 months and transduced cells were not eliminated. CONCLUSIONS: Lentiviral vectors that express UGT1A1 reduce hyperbilirubinemia in immunocompetent Gunn rats for at least 6 months. The immune response against virally expressed UGT1A1 can be circumvented by inclusion of miR-142 target sequences, which reduce vector expression in antigen-presenting cells. This lentiviral-based gene therapy approach might be developed to treat patients with CN-I.


Assuntos
Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Vetores Genéticos , Glucuronosiltransferase/genética , Lentivirus/genética , Fígado/enzimologia , MicroRNAs/metabolismo , Animais , Anticorpos/sangue , Células Apresentadoras de Antígenos/imunologia , Bilirrubina/sangue , Biomarcadores/sangue , Síndrome de Crigler-Najjar/enzimologia , Síndrome de Crigler-Najjar/genética , Síndrome de Crigler-Najjar/imunologia , Modelos Animais de Doenças , Glucuronosiltransferase/biossíntese , Glucuronosiltransferase/imunologia , Células HeLa , Humanos , Masculino , Pré-Albumina/genética , Regiões Promotoras Genéticas , Estabilidade de RNA , RNA Mensageiro/metabolismo , Ratos , Ratos Gunn , Fatores de Tempo , Transdução Genética
7.
Liver Transpl ; 14(5): 688-94, 2008 May.
Artigo em Inglês | MEDLINE | ID: mdl-18433045

RESUMO

Liver cell transplantation in humans has been impeded by invariable loss of the graft. It is unclear whether graft loss is due to an immune response against donor hepatocytes. Transplantation with ABO-matched liver cells was performed in a patient with Crigler-Najjar type 1. After successful engraftment, there was a gradual loss of graft function. Solid-phase enzyme immunoassay testing and cell-complement cytotoxicity assays detecting preformed antibodies directed toward class I and/or class II human leukocyte antigen (HLA) molecules were negative. In contrast, a striking host alloresponse to either the HLA-B39 or C7 antigen was found, suggesting that a vigorous response to a defined mismatched HLA antigen contributed to graft loss in our patient. This study provides evidence that a T-cell-mediated immune mechanism could be responsible for human liver cell transplant graft loss. This finding warrants confirmation in future liver cell transplants in humans.


Assuntos
Síndrome de Crigler-Najjar/cirurgia , Rejeição de Enxerto/imunologia , Hepatócitos/transplante , Imunidade Celular , Transplante de Fígado , Linfócitos T/imunologia , Criança , Síndrome de Crigler-Najjar/imunologia , Feminino , Antígenos HLA-B/imunologia , Antígeno HLA-B39 , Antígenos HLA-C/imunologia , Hepatócitos/imunologia , Humanos , Reoperação , Fatores de Tempo , Transplante Homólogo , Falha de Tratamento
8.
Gene Ther ; 14(17): 1270-7, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17611583

RESUMO

Among inherited diseases of the liver, Crigler-Najjar type 1 disease (CN-1), which results from complete deficiency in bilirubin UDP-glucuronosyltransferase activity (B-UGT1), is an attractive target for gene therapy studies. Hyperbilirubinemic Gunn rats, a model of CN-1, were injected at 2 days of age with lentiviral or oncoretroviral vectors encoding the human B-UGT1. After injection, bilirubinemia was normalized for up to 95 weeks. Bilirubin conjugates were present in the bile, demonstrating liver transduction. PCR and enzyme activity analysis confirmed gene and phenotype correction in liver. We observed that when using a strong viral promoter, a complete correction was achieved with less than 5% of B-UGT1 copy per haploid genome and after a reconstitution of 12% B-UGT1 normal activity. Liver histology remained normal throughout the experiment and tissue distribution analysis revealed preferential hepatocyte transduction after systemic delivery. Finally, no adverse immune response occurred even after induction of nonspecific liver inflammation, suggesting immune ignorance to the therapeutic protein. Our present results document the lifelong safety of gene therapy for CN-1 with retroviral vectors. They offer a better delineation of liver gene correction level required to achieve complete correction of bilirubinemia and pave the way for future clinical application of gene therapy for inherited liver disorders.


Assuntos
Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , Glucuronosiltransferase/genética , Fígado/enzimologia , Retroviridae/genética , Animais , Animais Recém-Nascidos , Bilirrubina/sangue , Concanavalina A/farmacologia , Síndrome de Crigler-Najjar/imunologia , Feminino , Expressão Gênica , Engenharia Genética , Vetores Genéticos/genética , Proteínas de Fluorescência Verde/genética , Hepatócitos/enzimologia , Hepatócitos/virologia , Humanos , Injeções Intravenosas , Lentivirus/genética , Vírus da Leucemia Murina/genética , Fígado/virologia , Testes de Função Hepática , Masculino , Modelos Animais , Fenótipo , Ratos , Ratos Gunn , Fatores de Tempo , Transdução Genética/métodos , Transgenes
9.
Gene Ther ; 13(8): 672-7, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16267566

RESUMO

Gene therapy for inherited disorders might cause an immune response to the therapeutic protein. A solution would be to introduce the gene in the fetal or neonatal period, which should lead to tolerization. Lentiviral vectors mediate long-term gene expression, and are well suited for gene therapy early in development. A model for fetal or neonatal gene therapy is the inherited disorder of bilirubin metabolism, Crigler-Najjar disease (CN). The absence of bilirubin UDP-glucoronyltransferase (UGT1A1) activity in CN patients causes high serum levels of unconjugated bilirubin and brain damage in infancy. CN is attractive for the development of gene therapy because the mutant Gunn rat closely mimics the human disease. Injection of UGT1A1 lentiviral vectors corrected the hyperbilirubinemia for more than a year in rats injected as fetuses and for up to 18 weeks in rats injected the day of birth. UGT1A1 gene transfer was confirmed by the presence of bilirubin glucuronides in bile. All animals injected with UGT1A1 lentiviral vectors developed antibodies to UGT1A1. Animals injected with green fluorescent protein (GFP) lentiviral vectors did not develop antibodies to GFP. Our results indicate that fetal and neonatal gene therapy with immunogenic proteins such as UGT1A1 does not necessarily lead to tolerization.


Assuntos
Síndrome de Crigler-Najjar/imunologia , Síndrome de Crigler-Najjar/terapia , Terapia Genética/métodos , Vetores Genéticos/administração & dosagem , Glucuronosiltransferase/genética , Lentivirus/genética , Animais , Animais Recém-Nascidos , Anticorpos/sangue , Síndrome de Crigler-Najjar/embriologia , Feto , Vetores Genéticos/genética , Glucuronosiltransferase/imunologia , Proteínas de Fluorescência Verde/genética , Proteínas de Fluorescência Verde/imunologia , Tolerância Imunológica , Injeções , Fígado , Ratos , Ratos Gunn , Transdução Genética/métodos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...